Switch to
More onapp

Neuland Laboratories Ltd

NEULANDLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,269 cr, stock is ranked 753
High RiskStock is 3.31x as volatile as Nifty
1,734.950.00 (+0.00%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,269 cr, stock is ranked 753
High RiskStock is 3.31x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
35.56
PB RatioPB Ratio
2.70
Dividend YieldDiv. Yield
0.28%
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

67%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Neuland Laboratories Limited is a manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The Company operates through manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services. The Company’s capabilities include FBRM, research and development, peptide laboratory, poly block reactors, laboratory reactors, heating and cooling systems, hazardous and wet laboratory, PID Laboratory Unit-III, PID Laboratory B-S Unit-I, and other lab equipment. The Company has 3 manufacturing facilities and one R&D facility in Hyderabad.

Investor PresentationView older 

May 10, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

2019202020212022670.32766.60953.01953.1616.4416.2180.6363.82
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

General updates 
Announced OnNov 23, 2022

Board approved the transfer of Company¬タルs property situated at Nanakramguda, Hyderabad by way of perpetual lease, subject to receipt of requisite approvals | Download

Board approved the transfer of Company¬タルs property situated at Nanakramguda, Hyderabad by way of perpetual lease, subject to receipt of requisite approvals | Download

Appointment 
Announced OnNov 23, 2022

Appointment of Mr. Abhijit Majumdar, as the Chief Financial Officer (CFO) and KMP of the Company. | Download

Appointment of Mr. Abhijit Majumdar, as the Chief Financial Officer (CFO) and KMP of the Company. | Download

Cash Dividend 
Ex. DateJul 14, 2022

Final • Div/Share: ₹ 5

See all events